Leukaemia cutis Completed Phase 3 Trials for Sorafenib (DB00398)

Also known as: Leukemia Cutis

IndicationStatusPhase
DBCOND0006922 (Leukaemia cutis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01371981Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTreatment